Real-World Comparison of Trough- and Online-Bayesian-Calculator-Derived AUC0–24/MIC Target Attainment for Vancomycin Monitoring in Critically Ill Patients
Pharmaceuticals · 18.07.2026 · 19 (7) · 1109
DOI: 10.3390/ph19071109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 18.07.2026. Verfasst von Sufyan Alomair und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsaa 31982, Saudi Arabia. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Faisal University.
Abstract (Originalsprache)
Introduction
The preferred PK/PD goal for vancomycin is now AUC0–24/MIC-guided dosing, which requires two blood samples, additional time, increased cost, and possibly specialized staff, potentially limiting its use. Our study compared vancomycin target attainment using trough versus single-sample Bayesian AUC0–24/MIC in critically ill patients, using a validated online calculator.
Methods
This retrospective cohort study included adults aged ≥18 years with stable renal function who were receiving vancomycin. Exclusions were age under 18, unstable renal function, hemodialysis, missing data, or non-steady-state vancomycin. Steady-state troughs were obtained, and AUC0–24/MIC was calculated using ClinCalc. The primary endpoint was discordance in target attainment between trough (15–20 mg/L) and AUC0–24/MIC (400–600 mg·h/L). The secondary endpoint was AKI within 48 h of initiating vancomycin.
Results
The mean trough was 14.8 ± 8.0 mg/L, and the mean AUC0–24/MIC was 499.7 ± 201.3 mg·h/L. Trough levels were within target in 20%, and AUC0–24/MIC in 67%. The 3 × 3 cross-tabulation showed a significant association (χ2 = 27.33, p < 0.001), but only fair agreement (Cohen’s κ = 0.215) and a biased disagreement pattern (p < 0.001). Thirty-eight patients (38%) had “false alarming” results: trough < 15 mg/L despite AUC0–24/MIC ≥ 400 mg·h/L. Three patients (3.0%) showed “falsely reassuring” results: trough 15–20 mg/L with AUC0–24/MIC > 600 mg·h/L. The odds of supratherapeutic AUC0–24/MIC > 600 mg·h/L were tenfold higher in patients with trough 15–20 mg/L than in those below 15 mg/L (OR 10.24, p = 0.048).
Conclusions
In critically ill ICU patients, calculator-derived AUC0–24/MIC showed significant discordance with single-trough vancomycin monitoring, primarily indicating apparent under-exposure by trough criteria in patients with adequate AUC0–24/MIC levels, which may lead to unnecessary dose escalation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsaa 31982, Saudi Arabia.
- Almoosa Specialist Hospital, Al-Ahsaa 31982, Saudi Arabia.
ORCID-Profile: Sufyan Alomair, Fatimah Alsultan, Batool Alhassan
Förderung
- King Faisal University
Zitieren
APA
Alomair, S., Alsultan, Z., Alsultan, F., Alghadeer, F., Aljafar, A., Alkhawaldeh, A., Alherz, A., & Alhassan, B. (2026). Real-World Comparison of Trough- and Online-Bayesian-Calculator-Derived AUC0–24/MIC Target Attainment for Vancomycin Monitoring in Critically Ill Patients. Pharmaceuticals, 19(7), 1109. https://doi.org/10.3390/ph19071109
Vancouver
Alomair S, Alsultan Z, Alsultan F, Alghadeer F, Aljafar A, Alkhawaldeh A, et al. Real-World Comparison of Trough- and Online-Bayesian-Calculator-Derived AUC0–24/MIC Target Attainment for Vancomycin Monitoring in Critically Ill Patients. Pharmaceuticals. 2026;19(7):1109. doi:10.3390/ph19071109
BibTeX
@article{Alomair2026,
author = {Alomair, Sufyan and Alsultan, Zahra and Alsultan, Fatimah and Alghadeer, Fatimah and Aljafar, Alzahraa and Alkhawaldeh, Anas and Alherz, Ayat and Alhassan, Batool},
title = {Real-World Comparison of Trough- and Online-Bayesian-Calculator-Derived AUC0–24/MIC Target Attainment for Vancomycin Monitoring in Critically Ill Patients},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1109},
doi = {10.3390/ph19071109}
}
EUVIMED